HOME >> BIOLOGY >> NEWS
HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma

DALLAS July 30, 2003 AIDS patients with primary central nervous system lymphoma who receive the HAART "cocktail" therapy live much longer than those not treated with the therapy, researchers at UT Southwestern Medical Center at Dallas found.

A study published in today's issue of the journal AIDS reports that patients treated with HAART Highly Active Antiretroviral Therapy survived at least 22 months, compared with a median of 29 days for those who didn't take the prescription drug regimen.

"Traditionally, patients with primary central nervous system lymphoma have a very poor prognosis with a survival of only a few weeks to months after diagnosis," said Dr. Daniel Skiest, associate professor of internal medicine at UT Southwestern and the study's senior author.

Skiest, also the associate chief for clinical infectious diseases at UT Southwestern, reviewed records of AIDS patients diagnosed with central nervous system lymphoma at Parkland Memorial Hospital a 990-bed hospital serving Dallas County which is the primary teaching institution of Southwestern Medical School between 1995 and 2001 to determine the effects of HAART on survival rates.

During the six-year study, 25 patients were identified. Of those, 19 were definite cases of CNS lymphoma and six were probable cases. Six of seven patients treated with HAART survived at least one year and 10 months after diagnosis. The 18 who did not receive the therapy all died.

Of those who died, patients who received radiation therapy lived longer. Eleven patients who received neither HAART nor radiation had a median survival of only 29 days.

"While HAART has led to much better outcomes in many AIDS-related complications, it has not been clear whether there is a benefit of HAART in patients with primary CNS lymphoma," Skiest said. "Ours is only the second series to demonstrate a significant survival benefit. It is not yet clear whether the survival benefit is related to prev
'"/>

Contact: Rachel Horton
rachel.horton@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
30-Jul-2003


Page: 1 2

Related biology news :

1. Treatment With IL-2 Plus HAART Markedly Reduces HIV In Immune System "Hiding Places"
2. The Perils Of Discontinuing Therapy: Without HAART, Cytokines Stimulate HIV From Latently Infected Cells
3. Targeted therapy knocks out pediatric brain cancer in mice
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Columbia research to examine gene influence on severity of peridontal disease, therapy response
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. The search for a kinder, gentler chemotherapy
8. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
9. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
10. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
11. Jefferson Lab detector technology aids development of cystic fibrosis therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... , ... August 20, 2019 , ... ... and commercialization of bioactive technologies for the spine, today announced the 510(K) clearance ... a unique surface modification that is proven to improve osseointegration through superior hydrophilicity ...
(Date:8/15/2019)... TORONTO (PRWEB) , ... August 15, 2019 , ... ... finally passed. Now what? As serialization mandates become increasingly complex, and aggregation becomes ... their current serialization software is the best long-term solution. , Until now, most ...
(Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research ... EDT to learn about two common imaging methods in NAFLD/NASH to aid with early ... diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... , ... September 16, 2019 , ... ... via CNBC on Saturday, September 21st @11:00am ET. Check local listings for more ... Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to developing ...
(Date:9/11/2019)... ... September 10, 2019 , ... Catalent, the leading global provider ... and consumer health products, today announced that Alex Haig, Senior Director, Engineering will ... AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019. , On Wednesday, Sept. 18 ...
(Date:9/2/2019)... , ... September 02, 2019 , ... ... and in vitro diagnostics, has launched the industry’s first epigenetics data mining services ... meaning of epigenetic data and other data types. , Next generation sequencing in ...
(Date:8/27/2019)... HOUSTON (PRWEB) , ... August 27, 2019 , ... ... chain engineering firm, is pleased to announce it has promoted Consulting Engineer, Robert ... Solutions, Battista has added the responsibility of onboarding and mentoring new engineers as ...
Breaking Biology Technology:
Cached News: